If you had checked yahoo finance or nadaq.com, you would know he executed options:
HECHT PETER M Officer: 03/17/2015 Sell direct 125,000 at $15.6100, 4,141,417 shares owned post transaction
HECHT PETER M Officer 03/17/2015 Option Execute direct 125,000 at $1.5600, 4,266,417 shares owned post transaction
option price executed was $1.56, so those are evidently pretty old, pre-IPO options that probably came up on their expiration date.
Read more: http://www.nasdaq.com/symbol/irwd/insider-trades#ixzz3V1lqeBBv
As for share ownership (s. above, >4 million shares): to put it in perspective, the CEO of IRWD owns more shares than 141 of the 150 institutional investors in IRWD, compare:
http://www.nasdaq.com/symbol/irwd/institutional-holdings
I would encourage you to look up the CEO salaries for the CEO of IRWD, a company with a (profitable) product on the market, and the CEO of SGYP, a company with no FDA approved product, in the relevant SEC filings.
that's the real eye opener, IMHO.
Good luck !
The Lord's bond-servant must not be quarrelsome, but be kind to all, able to teach, patient when wronged, with gentleness correcting those who are in opposition, if perhaps God may grant them repentance leading to the knowledge of the truth
2Tim2:24-25
Recent IRWD News
- Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week® 2024 • Business Wire • 05/01/2024 11:30:00 AM
- Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call • Business Wire • 04/25/2024 08:01:00 PM
- Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD) • Business Wire • 03/28/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/08/2024 09:05:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 09:05:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:05:12 PM
- Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF) • Business Wire • 02/29/2024 11:00:00 AM
- Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference • Business Wire • 02/23/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 12:04:58 PM
- Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance • Business Wire • 02/15/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 02:01:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:53:45 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:50:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:42:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:39:29 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 01:35:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:05:21 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/09/2024 09:13:58 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/09/2024 09:11:46 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/09/2024 09:09:12 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/09/2024 09:05:04 PM
- Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call • Business Wire • 02/01/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:05:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:05:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/19/2024 09:05:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM